Utilizing AI to drive AAV-based gene delivery to the CNS
Cell & Gene Therapy Insights 2023 9(4), 495–502
Published: 29 May
Artificial intelligence and machine learning are entering an era of practical application in the cell and gene therapy space—with exciting early results. David McCall, Senior Editor,
BioInsights, speaks to David Huss, Chief Scientific Officer,
Shape Therapeutics, about ShapeTX’s application of AI across
the organization, from novel AAV capsid discovery and
development to honing core business practices.